RENMAB
Live / Registered — Registered (as of 06 Jan 2026)
What this means for you
Registered since 06 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88553807
- Registration number
- 8096103
- Mark type
- Stylized text
- Filed
- 31 Jul 2019
- Published for opposition
- 17 Aug 2021
- Registered
- 06 Jan 2026
- Attorney of record
- CYNTHIA JOHNSON WALDEN
Goods and services
- Class 005 — Pharmaceuticals: Medical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancer, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposes, namely, for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseases, namely, Active Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparation, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals
Owner
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., Daxing District, Beijing, CN
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., Daxing District, Beijing, CN
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., BEIJING, CN
- Beijing Biocytogen Co., Ltd., Beijing, CN
Prosecution history
- 06 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Dec 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 18 Dec 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Nov 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 13 Nov 2025 — USE AMENDMENT FILED
- 13 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 27 Oct 2025 — DIVISIONAL PROCESSING COMPLETE
- 18 May 2025 — DIVISIONAL REQUEST RECEIVED
- 23 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 1 GRANTED
- 18 May 2025 — SOU EXTENSION 1 FILED
- 01 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 19 May 2025 — SOU TEAS EXTENSION RECEIVED